Evidence map›Paper›PMID 37839000›Full record

Trial reportRadiological physics and technology2023

Development and evaluation of a novel water-based pigment marker for radiation therapy skin marking.

Shinichi Nakayama, Miduki Hirose, Soichiro Kaneshige, Kenji Nakamura, Yukinori Matsuo, Hajime Monzen

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Radiological physics and technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Evaluation of tattoo reliability in breast cancer re-irradiation.Technical innovations & patient support in radiation oncology · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shinichi NakayamaDivision of Clinical Radiology Service, Okayama Central Hospital, 6-3, Ishimakitamachi, Kitaku, Okayama, 700-0017, Japan.
Miduki HiroseDepartment of Radiation Oncology, Okayama Central Hospital, 6-3, Ishimakitamachi, Kitaku, Okayama, 700-0017, Japan.
Soichiro KaneshigeDepartment of Radiation Oncology, Okayama Central Hospital, 6-3, Ishimakitamachi, Kitaku, Okayama, 700-0017, Japan.
Kenji NakamuraDepartment of Medical Physics, Graduate School of Medical Sciences, Kindai University, 377-2, Onohigashi, Osakasayama, Osaka, 589-8511, Japan.
Yukinori MatsuoDepartment of Radiation Oncology, Faculty of Medicine, Kindai University, 377-2, Onohigashi, Osakasayama, Osaka, 589-8511, Japan.
Hajime MonzenDivision of Clinical Radiology Service, Okayama Central Hospital, 6-3, Ishimakitamachi, Kitaku, Okayama, 700-0017, Japan. hmon@med.kindai.ac.jp.
Kindai University · JPOkayama Central Hospital · JP

Funding

Japan Society for the Promotion of Science 23K07194
6 · The paper itself

Abstract

Skin marks are widely used in external radiation therapy to ensure the accuracy of the irradiation position. However, conventional skin markers contain harmful substance, so we developed an alternative skin marker. The purpose of this study was to investigate the feasibility of using a novel water-based pigment marker comprising safe materials commonly used in cosmetics for clinical radiation therapy. We investigated various properties of the marker, namely marker longevity, color variety, line visibility, ink bleeding, and line durability, and improved the marker in response to the feel when drawing or being drawn on. The durability of the ink was evaluated by simultaneously applying the new marker and oil-based pen and comparing the period until the marks faded and became invisible. In clinical trial, we applied marks on the skin of 56 patients over three months to observe symptoms and visible changes in the skin. There were no complications of discomfort or pain, owing to the improvements in the marker tip. The marks drawn on the arms of volunteers with the new marker and the oil-based pen remained visible for a mean of 7.2 days and 3.6 days, respectively (P value < 0.001). The percentages of participants with no symptoms and no visible changes were 100%, respectively. We developed an alternative skin marker that complies with current regulatory standards by excluding crystal violet. The newly developed marker has features suitable for clinical use, such as resistance to smudging and water, marker tip shape and texture, and color variations.

Indexed as

Gentian VioletSkinHumansReference StandardsGentian VioletCrystal violetRadiation therapySafe materialsSkin markingWater-based pigment marker

Identifiers

PMID37839000
OpenAlexW4387655354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.